Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.

Key Takeaways Summit Therapeutics shares dropped 14% Monday as it reported a fourth-quarter adjusted loss nearly double that ...

We recently published a list of 10 Stocks Drop The Most Amid Investor Caution. In this article, we are going to take a look ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Summit's Co-CEOs, Bob Duggan and Dr. Maky Zanganeh, expressed optimism about the collaboration's ability to accelerate the ...

Summit Therapeutics, Inc. shares rebounded in after-hours trading on Monday after a 14% selloff during regular hours, with ...

Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF ...

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.

EST Summit Therapeutics (SMMT) jumps 5% to $23.19 after trial pact with Pfizer (PFE)Discover the Best Stocks and Maximize Your Portfolio: ...

Florida, USA-based Summit Therapeutics saw its share rise 6.2% to $23.50 pre-market on the news of a clinical trial ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...